ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

04 May 2022 15:05:03 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

02 May 2022 15:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

05 Apr 2022 15:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

09 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference

02 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

18 Feb 2022 10:35:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

15 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

02 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022

24 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition

10 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

29 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

13 Dec 2021 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

02 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients

11 Nov 2021 16:52:49 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results

03 Nov 2021 15:05:02 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021

06 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease

02 Oct 2021 12:15:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status

30 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle

21 Sep 2021 15:05:00 By Nasdaq GlobeNewswire